Loading...
Loading...
SQZ| Name | Value |
|---|---|
| Revenues | 12.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 12.0M |
| Operating Expense | 21.2M |
| Operating I/L | -14.0M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.6M |
| Pretax | -13.5M |
| Income Tax Expense | -44.0M |
| Net Income/Loss | 30.5M |
SQZ Biotechnologies Company is a clinical-stage biotechnology company specializing in developing cell therapies for cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate, SQZ-PBMC-HPV, is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors. Additionally, it has platforms in development such as SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers.
